Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) announced an expansion of its development strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE